AR029451A1 - A COMPOSITION FOR USE IN THE BREAST CANCER THERAPY IN HUMAN BEINGS AND A PRODUCT FOR USE IN SUCH THERAPY - Google Patents

A COMPOSITION FOR USE IN THE BREAST CANCER THERAPY IN HUMAN BEINGS AND A PRODUCT FOR USE IN SUCH THERAPY

Info

Publication number
AR029451A1
AR029451A1 ARP000102365A ARP000102365A AR029451A1 AR 029451 A1 AR029451 A1 AR 029451A1 AR P000102365 A ARP000102365 A AR P000102365A AR P000102365 A ARP000102365 A AR P000102365A AR 029451 A1 AR029451 A1 AR 029451A1
Authority
AR
Argentina
Prior art keywords
therapy
breast cancer
product
composition
human beings
Prior art date
Application number
ARP000102365A
Other languages
Spanish (es)
Inventor
Salle Enrico Di
Tiziana Zaccheo
Michele Tedeschi
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR029451A1 publication Critical patent/AR029451A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto para su uso en la terapia para el cáncer de mamas en seres humanos, que contiene un agente antineoplásico y un inhibidor de aromatasa, en cantidades efectivas para producir un efecto antitumoral superaditivo, para su administracion en forma separada, simultánea o secuencial en la terapia para el cáncer de mamas en seres humanos.A product for use in therapy for breast cancer in humans, which contains an antineoplastic agent and an aromatase inhibitor, in amounts effective to produce a superaditive antitumor effect, for administration separately, simultaneously or sequentially in the therapy for breast cancer in humans.

ARP000102365A 1999-05-18 2000-05-17 A COMPOSITION FOR USE IN THE BREAST CANCER THERAPY IN HUMAN BEINGS AND A PRODUCT FOR USE IN SUCH THERAPY AR029451A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911582.6A GB9911582D0 (en) 1999-05-18 1999-05-18 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound

Publications (1)

Publication Number Publication Date
AR029451A1 true AR029451A1 (en) 2003-07-02

Family

ID=10853700

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102365A AR029451A1 (en) 1999-05-18 2000-05-17 A COMPOSITION FOR USE IN THE BREAST CANCER THERAPY IN HUMAN BEINGS AND A PRODUCT FOR USE IN SUCH THERAPY

Country Status (6)

Country Link
EP (1) EP1178831A1 (en)
JP (1) JP2003512301A (en)
AR (1) AR029451A1 (en)
AU (1) AU3820700A (en)
GB (1) GB9911582D0 (en)
WO (1) WO2000069467A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030043955A (en) * 2000-09-08 2003-06-02 파마시아 이탈리아 에스.피.에이. Exemestane as chemopreventing agent
EA200300572A1 (en) * 2000-11-16 2004-06-24 Фармация Энд Апджон Компани COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES
EP2762140B1 (en) 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
CZ299756B6 (en) * 2001-05-16 2008-11-12 Novartis Ag Combination containing N-(5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine intended for the treatment of proliferative diseases
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
ES2694582T3 (en) 2011-01-31 2018-12-21 Lucolas-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants
CN107405353B (en) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 Method for reducing mammographic breast density and/or breast cancer risk
WO2017066827A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Also Published As

Publication number Publication date
AU3820700A (en) 2000-12-05
GB9911582D0 (en) 1999-07-21
JP2003512301A (en) 2003-04-02
WO2000069467A1 (en) 2000-11-23
EP1178831A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
AR033555A1 (en) PRODUCT FOR THE TREATMENT OF POSITIVE STROGEN RECEIVER CARCINOMA, AND USE OF THIS PRODUCT TO PREPARE MEDICINES
AR028296A1 (en) SYNERGISTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CO4290346A1 (en) Azithromycin Controlled Release Dosage Forms
ES2148838T3 (en) ANTI-SENSE OLIGONUCLEOTIDES AGAINST THE ALP REGULATORY SUBUNIT OF PROPETIN KINASE, DEPENDENT ON CAMP FOR THE TREATMENT OF CANCER.
TR200000576T1 (en) A method for applying liposomal encapsulated taxane
AR019855A1 (en) USE OF PEG-IFN-ALFA AND RIBAVIRINE CONJUGATES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC HEPATITIS C
PA8479201A1 (en) DERIVATIVES OF HYDROXY ACID-HYDROXAMIC PIPECOLATE
AR045179A1 (en) USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
AR082579A2 (en) A PHARMACEUTICAL COMPOSITION SPONTANEALLY AVAILABLE FOR ORAL ADMINISTRATION, USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER, METHOD FOR INCREASING BIODISPONIBILITY LEVELS OR REDUCING ITS VARIABILITY
AR027355A1 (en) THIAZOLIDINCARBOXILIC ACIDS
DK1259240T3 (en) Agents, such as nicotinamide or CADPR, for the treatment of skin diseases
UY26456A1 (en) COMPOUNDS THAT FIX THE G-QUADRUPLEX STRUCTURE OF TELOMERES, TRIAZINS FOR THE APPLICATION OF SUCH COMPOUNDS, THE USE OF SUCH COMPOUNDS AS PHARMACEUTICAL PRODUCTS AND INCLUDING THERAPEUTICAL ASSOCIATIONS.
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
MY138883A (en) Use of asiatic acid for treatment of cencer
AR029451A1 (en) A COMPOSITION FOR USE IN THE BREAST CANCER THERAPY IN HUMAN BEINGS AND A PRODUCT FOR USE IN SUCH THERAPY
AR024564A1 (en) COMPOSITION THAT INCLUDES SPPHINGOMYELINASE FOR USE AS A DIETARY PREPARATION, DIETARY SUPPLEMENT OR PHARMACEUTICAL PRODUCT
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
ES2172171T3 (en) MEDICINAL PRODUCT, CONTAINING YOHIMBINE AND ARGININE, FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS.
MXPA02010184A (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia.
ATE399558T1 (en) ANTI-TUMORAL FORMULATIONS CONTAINING DEFIBROTIDE ALONE OR IN COMBINATION WITH OTHER ANTITUMORAL AGENTS
HUP0203153A2 (en) Combination chemotherapy
ATE294585T1 (en) PREVENTION OF COLORECTAL CANCER
CY1107227T1 (en) TREATMENT OF AUTOIMMUNE DISEASES WITH AMERICAN GINSENG EXTRACT
AR024981A1 (en) COMPOSITION FOR THE PREVENTION AND TREATMENT OF RINON DYSFUNCTIONS AND DISEASES
TR200002847T2 (en) Form VI 5, 6-dichloro-2- (isopropylamino) -1- (beta-L-ribofuranosyl) -1H-benzimidazole.

Legal Events

Date Code Title Description
FB Suspension of granting procedure